We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease.
【저자키워드】 SARS-CoV-2, hamsters, monoclonal antibody, Prophylaxis, ZRC3308, 【초록키워드】 COVID-19, Treatment, therapy, B.1.351, SARS-COV-2 infection, monoclonal antibody, SARS-CoV-2 variant, B.1.617.2, in vitro, Prophylactic, binding affinity, Spike protein, COVID-19 treatment, Epitopes, antibody cocktail, B.1.1.7, SARS-CoV-2 spike protein, Neutralizing, circulation, epitope, mAbs, mAb, AY.1, severe disease, B.1, binding affinities, COVID-19 case, therapeutic activity, RBD of SARS-CoV-2, effective, reduced, appear, demonstrated, 1:1, immune effector function, progressed, 【제목키워드】 hamster, cocktail, show,